Compare REA & STIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REA | STIM |
|---|---|---|
| Founded | 2021 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Medical/Dental Instruments |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 144.6M | 120.4M |
| IPO Year | 2026 | 2018 |
| Metric | REA | STIM |
|---|---|---|
| Price | $6.51 | $1.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $24.53 | $6.00 |
| AVG Volume (30 Days) | 158.0K | ★ 1.2M |
| Earning Date | 11-24-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.25 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $52,776,000.00 |
| Revenue This Year | N/A | $8.63 |
| Revenue Next Year | N/A | $9.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.20 | $0.80 |
| 52 Week High | $17.84 | $3.44 |
| Indicator | REA | STIM |
|---|---|---|
| Relative Strength Index (RSI) | 36.71 | 35.12 |
| Support Level | $6.20 | $1.19 |
| Resistance Level | $9.31 | $2.31 |
| Average True Range (ATR) | 0.80 | 0.27 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 5.08 | 9.09 |
Rare Earths Americas Inc is an exploration stage company focused on advancing projects related to rare earth minerals. Its activities include evaluating mineralization and assessing the characteristics and economic potential of its assets. Its portfolio includes the Shiloh Project in Georgia, United States; the Alpha Project in Bahia, Brazil; and the Constellation Project in Minas Gerais, Brazil. It also holds additional early-stage exploration projects, including the Homer Project in Goias, Brazil, and the Liberty Peak Project in Georgia, United States. The company has two reportable segments due to their geographical location: United States Mining Operations and Brazil Mining Operations.
Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.